Two Sigma Advisers
AARD

Two Sigma Advisers’s Aardvark Therapeutics AARD Stock Holding History

Two Sigma Advisers’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,200
Closed -$344K – 2295
2025
Q4 		$344K Buy
26,200
+500
+2% +$6.24K ﹤0.01% 1938
2025
Q3 		$342K Buy
+25,700
New +$290K ﹤0.01% 1919

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers's AARD Position: Q1 2026 in Review

Two Sigma Advisers sold out of Aardvark Therapeutics (AARD) in Q1 2026, closing a stake of 26,200 shares — an estimated $344K sold.

Two Sigma Advisers first reported a position in AARD in Q3 2025 and held it in 2 quarters. The position peaked at $344K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Two Sigma Advisers reported no remaining Aardvark Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 26,200 Aardvark Therapeutics shares in Q1 2026, an estimated $344K.
  • Two Sigma Advisers first reported a position in Aardvark Therapeutics in Q3 2025 and held it in 2 quarters.
  • Two Sigma Advisers's Aardvark Therapeutics position peaked at $344K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.